Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm II Phase Study of Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy

NCT06041724 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06041724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm II Phase Study of Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
September 18, 2023
Completion date
March 18, 2026
Enrollment
46 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced mucosal melanoma